SOURCE: Gene Express, Inc.

December 04, 2006 08:30 ET

Gene Express Chairman Provides Updates on Corporate Developments

First SEM Center™ License Sold to Gene Logic; Clinical Project With Global Pharmaceutical Company Underway; Continued Momentum in Strategic Partnerships

TOLEDO, OH -- (MARKET WIRE) -- December 4, 2006 -- Gene Express, Inc.'s Chairman, Al Pollock, shared updates on the Company's development strategy with shareholders today.

Mr. Pollock highlighted several achievements over the past three quarters, including the licensing of the Company's first commercial Standardized Expression Measurement (SEM) Center™ to Gene Logic and a clinical project with a global pharmaceutical company for quantitative multi-gene standardized expression measurement. In addition, Mr. Pollock shared the submission of three significant proposals for standardized expression measurement to leading commercial and research institutions, which the Company expects to be signed in the first quarter of 2007.

Mr. Pollock noted that Gene Express and a significant player in the microarray field are in discussions regarding the use of StaRT-PCR™ technology to standardize microarrays.

He also stated that Gene Express, a top pharmaceutical company, and a leading diagnostic company are in the process of defining the roadmap and execution plan to bring a compound and a molecular diagnostic test to market in parallel. The theranostic test would segment the patient population as well as determine proper dosages for an individual patient. This compound would be a late-stage oncology compound.

Mr. Pollock reviewed some enhancements to the Gene Express team, including Nick V. Lazaridis, Ph.D., as President; John C. Anders, Ph.D., as Vice President of Operations; Colette Saccomanno, Ph.D., as Director of Business Development; Keller Pollock as Market Manager; Chuck Knight as SEM Center™ Team Leader; and Brad Austermiller as SEM Center™ Software Specialist. Each of these professionals brings extensive experience in the pharmaceutical development market.

"We have had three strong quarters of executing on our strategic plan in 2006," said Mr. Pollock. "Gene Express has established itself as a meaningful player in the pharmaceutical development industry and we are successfully turning our strategic relationships into revenue drivers. Achieving the first SEM Center™ license was a significant milestone in our development and we have laid the groundwork for several other licensing agreements and projects in the coming quarters. We have the right team in place to continue our momentum and look forward to sharing additional developments with our shareholders."

About Gene Express, Inc.

Gene Express, Inc. accelerates and enables drug development by providing standardized genomic data. The Company's proprietary and patented StaRT-PCR™ (Standardized Reverse Transcriptase Polymerase Chain Reaction) platform technology for measuring gene expression levels in cells, tissue and blood is being used by numerous pharmaceutical concerns, as well as leading academic centers. The Company's $3 billion focus market for licensing and contract services includes the drug development, academic and molecular diagnostics segments. Additional information is available on the Company's website at

Any forecasts, plans, projections and other information contained in this press release describing events or results that may occur in the future are "forward-looking statements" as defined in the United States Private Securities litigation Reform Act of 1995. Forward-looking statements are subject to risks, uncertainties and important factors that are beyond the control of the Company that could cause actual results and events to differ materially from the results presently anticipated or projected. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to this cautionary statement. All forward-looking statements contained herein speak only as of the date of this release and are based on current expectations. The Company disclaims any obligation to update or revise any forward-looking statements.

Contact Information

  • Contact:
    Rachel Levine
    The Global Consulting Group
    Tel: 646-284-9439
    E: Email Contact